Maxence Peigné

Mar 9, 2025 | msn.com | Shanti Das |Maxence Peigné

Microsoft Cares About Your PrivacyMicrosoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will personalise the content and ads that you see. You can select ‘I Accept’ to consent to these uses or click on ‘Manage preferences’ to review your options and exercise your right to object to Legitimate Interest where used.

Mar 6, 2025 | euobserver.com | Paulo Pena |Harald Schumann |Maxence Peigné

This story is part of an investigation led by Investigate Europe, a journalism team which produces cross-border investigations. The project is being published with media partners in 10 countries, including Amphora Media (Malta), ARD (Germany), Delfi (Estonia) Die Zeit (Germany), EU Observer (Belgium), Il Fatto Quotidiano (Italy), InfoLibre (Spain), Irpi Media (Italy), the Observer (UK), Partizan (Hungary), Reporters United (Greece) and RTP (Portugal).

Sep 24, 2024 | euobserver.com | Pascal Hansens |Harald Schumann |Maxence Peigné

Successive EU Commission presidents have proclaimed their commitment to defending the rule of law. At the start of her first term as president, Ursula von der Leyen declared that “Lady Justice is blind – she will defend the rule of law wherever it is attacked.”However, this rhetoric does not always translate into action.

Jun 13, 2024 | euobserver.com | Eurydice Bersi |Lorenzo Buzzoni |Maxence Peigné

InvestigationPatients suffering from cancer or other serious diseases rarely realise that their fate can depend on secret price deals struck between state officials and pharma executives, according to research by Investigative Europe. “The negotiation is totally secret. Everything moves around in sealed envelopes, changing hands with signatures,” one negotiator from a mid-sized EU country reveals.

Jun 13, 2024 | thejournal.ie | Maxence Peigné |Eurydice Bersi

GOVERNMENTS ACROSS EUROPE – including Ireland – are being charged up to 20 times what it costs to produce a ‘miracle’ drug for cystic fibrosis. The production cost of the drug Kaftrio could be as low as just €5,200 per patient per year and be profitable, a team of British scientists has calculated; yet governments are being charged an estimated €70,000 to over €100,000 for these and similar medicines by the US biotech firm Vertex Pharmaceuticals.Pharmaceuticals.